Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224 · see citing works

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.

Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · see citing works

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · see citing works

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290 · see citing works

The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene

Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789 · see citing works

c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling

Grigoriadis, A. E., Wang, Z., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260 · see citing works

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i>¹

Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · see citing works

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 996 · see citing works

Requirement for NF-κB in osteoclast and B-cell development

Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes &amp; Development · doi:10.1101/gad.11.24.3482 · Cited by 996 · see citing works

Osteopetrosis in mice lacking NF-κB1 and NF-κB2

Iotsova, V., Caamaño, J., Loy, J. K., Yang, Y., Lewin, A. C., & Bravo, R. (1997) · Nature Medicine · doi:10.1038/nm1197-1285 · Cited by 990 · see citing works

Early Lethality, Functional NF-κB Activation, and Increased Sensitivity to TNF-Induced Cell Death in TRAF2-Deficient Mice

Yeh, W., Shahinian, A., Speiser, D. E., Kraunus, J., Billia, F., Wakeham, A. C., de la Pompa, J. L., Ferrick, D. A., Hum, B., Iscove, N. N., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80391-x · Cited by 798 · see citing works

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · see citing works

TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

Fuller, K., Wong, B., Fox, S. W., Choi, Y., & Chambers, T. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.997 · Cited by 562 · see citing works

Advances in Bone Biology: The Osteoclast*

Roodman, G. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-308 · Cited by 553 · see citing works

The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor

Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., & Choi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28355 · Cited by 458 · see citing works

Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)

Darnay, B. G., Haridas, V., Ni, J., Moore, P. A., & Aggarwal, B. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20551 · Cited by 414 · see citing works

Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines

Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9394 · Cited by 311 · see citing works

Targeted Disruption of TRAF3 Leads to Postnatal Lethality and Defective T-Dependent Immune Responses

Xu, Y., Cheng, G., & Baltimore, D. (1996) · Immunity · doi:10.1016/s1074-7613(00)80497-5 · Cited by 243 · see citing works

ATAR, a Novel Tumor Necrosis Factor Receptor Family Member, Signals through TRAF2 and TRAF5

Hsu, H., Solovyev, I., Colombero, A. M., Elliott, R., Kelley, M. J., & Boyle, W. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13471 · Cited by 180 · see citing works

Hypocalcemic Effect of Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in the Thyroparathyroidectomized Rat

Yamamoto, M., Murakami, T., Nishikawa, M., Tsuda, E., Mochizuki, S.-I., Higashio, K., Akatsu, T., Motoyoshi, K., & Nagata, N. (1998) · Endocrinology · doi:10.1210/endo.139.9.6290 · Cited by 65 · see citing works

Osteoclast differentiation and activation

Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · see citing works

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · see citing works

RANK is essential for osteoclast and lymph node development.

Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes &amp; Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · see citing works

Inflammatory and immune pathways in the pathogenesis of periodontal disease

Cekici, A., Kantarci, A., Hasturk, H., & Van Dyke, T. E. (2014) · Periodontology 2000 · doi:10.1111/prd.12002 · Cited by 1,415 · see citing works

Minireview: The OPG/RANKL/RANK System

Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · see citing works

Denosumab in postmenopausal women with low bone mineral density.

McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228 · see citing works

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.

Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756 · see citing works

Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α

Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705 · see citing works

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works

Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors.

Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, D. M., & Suda, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1741 · Cited by 693 · see citing works

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599 · see citing works

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works

Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.

Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563 · see citing works

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550 · see citing works

Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun repression.

Shevde, N. K., Bendixen, A. C., Dienger, K. M., & Pike, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130200197 · Cited by 502 · see citing works

Developmental origin, functional maintenance and genetic rescue of osteoclasts

Jacome-Galarza, C. E., Percin, G. I., Muller, J. T., Mass, E., Lazarov, T., Eitler, J., Rauner, M., Yadav, V. K., Crozet, L., Bohm, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1105-7 · Cited by 475 · see citing works

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452 · see citing works

The Cytokine RANKL Produced by Positively Selected Thymocytes Fosters Medullary Thymic Epithelial Cells that Express Autoimmune Regulator

Hikosaka, Y., Nitta, T., Ohigashi, I., Yano, K., Ishimaru, N., Hayashi, Y., Matsumoto, M., Matsuo, K., Penninger, J. M., Takayanagi, H., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.018 · Cited by 433 · see citing works

RANK/RANKL: Regulators of Immune Responses and Bone Physiology

Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420 · see citing works

Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis

Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., & Osdoby, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010153200 · Cited by 398 · see citing works

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391 · see citing works

Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator

Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T., & Takeya, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205063200 · Cited by 377 · see citing works

Mechanisms of sex steroid effects on bone

Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380 · see citing works

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376 · see citing works

Pathophysiology of Age-Related Bone Loss and Osteoporosis

Khosla, S., & Riggs, B. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.009 · Cited by 376 · see citing works

Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis

Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368 · see citing works

RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling

Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309 · see citing works

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282 · see citing works

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281 · see citing works

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258 · see citing works

The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications

Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246 · see citing works

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244 · see citing works

IL-1 plays an important role in the bone metabolism under physiological conditions

Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226 · see citing works

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · see citing works

Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*

Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215 · see citing works

17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.

Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194 · see citing works

Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB

Cappellen, D., Luong-Nguyen, N.-H., Bongiovanni, S., Grenet, O., Wanke, C., & Šuša, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200434200 · Cited by 184 · see citing works

NF-κB p50 and p52 Expression Is Not Required for RANK-Expressing Osteoclast Progenitor Formation but Is Essential for RANK- and Cytokine-Mediated Osteoclastogenesis

Xing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165 · see citing works

Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone.

Menaa, C., Reddy, S. V., Kurihara, N., Maeda, H., Anderson, D., Cundy, T., Cornish, J., Singer, F. R., Bruder, J. M., & Roodman, G. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9133 · Cited by 154 · see citing works

Soluble RANKL and risk of nontraumatic fracture.

Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146 · see citing works

The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis

Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1015 · Cited by 129 · see citing works

Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation

Zaiss, M. M., Sarter, K., Hess, A., Engelke, K., Böhm, C., Nimmerjahn, F., Voll, R., Schett, G., & David, J. (2010) · Arthritis &amp; Rheumatism · doi:10.1002/art.27535 · Cited by 122 · see citing works

Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand

Schneeweis, L. A., Willard, D., & Milla, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506366200 · Cited by 116 · see citing works

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103 · see citing works

Dosage analysis of the 7q11.23 Williams region identifies <i>BAZ1B</i> as a major human gene patterning the modern human face and underlying self-domestication

Zanella, M., Vitriolo, A., Andirko, A., Martins, P. T., Sturm, S., O’Rourke, T., Laugsch, M., Malerba, N., Skaros, A., Trattaro, S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw7908 · Cited by 101 · see citing works

Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis

Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., Mao, M., Kostenuik, P., Dunstan, C. R., Lacey, D. L., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0245 · Cited by 100 · see citing works

Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling.

WHYTE, M. P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.016 · Cited by 95 · see citing works

DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process.

Mori, K., Le Goff, B., Charrier, C., Battaglia, S., Heymann, D., & Rédini, F. (2007) · Bone · doi:10.1016/j.bone.2006.11.006 · Cited by 95 · see citing works

Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive‐therapy periodontitis patients

Lappin, D. F., Sherrabeh, S., Jenkins, W. M. M., & Macpherson, L. M. D. (2007) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2007.01048.x · Cited by 90 · see citing works

The origins and formation of bone-resorbing osteoclasts

Elson, A., Anuj, A., Barnea-Zohar, M., & Reuven, N. (2022) · Bone · doi:10.1016/j.bone.2022.116538 · Cited by 95 · see citing works

Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders

Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91 · see citing works

Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.

Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309690200 · Cited by 92 · see citing works

Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing.

Flick, L. M., Weaver, J. M., Ulrich‐Vinther, M., Abuzzahab, F., Zhang, X., Dougall, W. C., Anderson, D., O'Keefe, R. J., & Schwarz, E. M. (2003) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(03)00011-1 · Cited by 82 · see citing works

Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.

Campagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis &amp; Rheumatism · doi:10.1002/art.10369 · Cited by 78 · see citing works

PU.1 and NFATc1 mediate osteoclastic induction of the mouse β₃ integrin promoter

Crotti, T. N., Sharma, S. M., Fleming, J. D., Flannery, M. R., Ostrowski, M. C., Goldring, S. R., & McHugh, K. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21344 · Cited by 76 · see citing works

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77 · see citing works

SQSTM1 and Paget?s Disease of Bone

Layfield, R., & Hocking, L. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0041-0 · Cited by 76 · see citing works

Substance P modulates bone remodeling properties of murine osteoblasts and osteoclasts

Niedermair, T., Schirner, S., Seebröker, R., Straub, R. H., & Grässel, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-27432-y · Cited by 74 · see citing works

Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71 · see citing works

Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation

Souza, P. P. C., & Lerner, U. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01663 · Cited by 67 · see citing works

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis

Skoumal, M., Kolarz, G., Haberhauer, G., Woloszczuk, W., Hawa, G., & Klingler, A. (2005) · Rheumatology International · doi:10.1007/s00296-004-0579-1 · Cited by 66 · see citing works

OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation

Tat, S. K., Padrines, M., Theoleyre, S., Couillaud-Battaglia, S., Heymann, D., Redini, F., & Fortun, Y. (2006) · Bone · doi:10.1016/j.bone.2006.03.016 · Cited by 63 · see citing works

Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs

He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58 · see citing works

Effect of smoking on concentrations of receptor activator of nuclear factor κ B ligand and osteoprotegerin in human gingival crevicular fluid

Tang, T. H., Fitzsimmons, T. R., & Bartold, P. M. (2009) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2009.01444.x · Cited by 52 · see citing works

Osteoprotegerin expression in dendritic cells increases with maturation and is NF‐κB‐dependent

Schoppet, M., Henser, S., Ruppert, V., Stübig, T., Al‐Fakhri, N., Maisch, B., & Hofbauer, L. C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21129 · Cited by 45 · see citing works

Bone circuitry and interorgan skeletal crosstalk

Zaidi, M., Kim, S.-M., Mathew, M., Korkmaz, F., Sultana, F., Miyashita, S., Gumerova, A. A., Frolinger, T., Moldavski, O., Barak, O., et al. (2023) · eLife · doi:10.7554/elife.83142 · Cited by 45 · see citing works

Plasma osteoprotegerin levels are decreased in smoker chronic periodontitis patients

Özçaka, Ö., Nalbantsoy, A., Köse, T., & Buduneli, N. (2010) · Australian Dental Journal · doi:10.1111/j.1834-7819.2010.01261.x · Cited by 36 · see citing works

RANKL/RANK pathway and its inhibitor RANK-Fc in uterine leiomyoma growth

Ikhena, D. E., Liu, S., Kujawa, S., Esencan, E., Coon, J. S., Robins, J., Bulun, S. E., & Yin, P. (2018) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2017-01585 · Cited by 26 · see citing works

Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.

Bateman, T. A., Dunstan, C. R., Lacey, D. L., Ferguson, V. L., Ayers, R. A., & Simske, S. J. (2001) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(00)00057-7 · Cited by 22 · see citing works

SIRT2 deficiency prevents age-related bone loss in rats by inhibiting osteoclastogenesis

Jing, Y., Zhou, Y., Zhou, F., Wang, X., Tao, B., Sun, L., Liu, J., & Zhao, H. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.7.12 · Cited by 22 · see citing works

Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.

Neumann, T., Oelzner, P., Petrow, P. K., Thoss, K., Hein, G., Stein, G., & Bräuer, R. (2006) · Inflammation Research · doi:10.1007/s00011-005-0005-5 · Cited by 12 · see citing works

Electrospun Poly(L-lactide-co-ε-caprolactone) Nanofibers with Hydroxyapatite Nanoparticles Mimic Cellular Interplay in Bone Regeneration

Šebová, E., Leal, F., Klusáček Rampichová, M., Nirwan, V. P., Fahmi, A., Costa, P. F., & Filová, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115383 · Cited by 4 · see citing works

Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis

Samara, S., Dailiana, Z. H., Chassanidis, C., Koromila, T., Papatheodorou, L. K., Malizos, Κ. Ν., & Κollia, P. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.10.014 · Cited by 37 · see citing works

Rank/Rankl/opg: literature review.

(2011) · PubMed · Cited by 170 · see citing works

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review)

Liu, W. X., & Zhang, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3152 · Cited by 218 · see citing works

Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head.

Xiong, M., Liu, L.-Q., Liu, S.-Q., Liu, Z., & Gao, H. (2016) · Europe PMC (PubMed Central) · Cited by 11 · see citing works

Expression Profiles of Receptor Activator of Nuclear Factor κB Ligand, Receptor Activator of Nuclear Factor κB, and Osteoprotegerin Messenger RNA in Aged and Ovariectomized Rat Bones

Ikeda, T., Utsuyama, M., & Hirokawa, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1416 · Cited by 107 · see citing works